secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001516551-24-000034
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience appoints Dr. Annalisa Jenkins to board; director Dalesandro to resign Aug 1
--------------------------------------------------------------------------------

- Dr. Annalisa Jenkins appointed to board effective Feb 29, 2024, filling newly created eighth seat.
- Dr. Jenkins receives annual cash retainer of $40,000 plus committee retainers; option for 40,000 shares vesting over 1 year.
- Director Margaret Dalesandro to resign effective Aug 1, 2024, citing no disagreement with company.
- Dr. Jenkins brings 25+ years pharma/biotech experience including roles at Merck Serono, BMS, and as CEO of Dimension Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000034/0001516551-24-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000034/skye-20240229.htm
  HTML page:      https://secwatch.observer/filing/0001516551-24-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer